May 10-11, 2022 Webconference
The Longwood Healthcare Leaders Spring meeting is centered on MIT’s Koch Institute via webconference with leading biopharma CEOs, heads of R&D, top academic researchers, and healthcare investors, co-hosted by Nobel laureate and Biogen/Alnylam co-founder Phil Sharp.
These meetings are focused on accelerating the translation of discoveries into medicines to help patients; substantial donations enabled by these meetings benefit Life Science Cares, The Boston Foundation, BSO, Harvard Medical School, MIT, and other charities. The Spring 2021 agenda is included below.
PAST AGENDA | APRIL 5-6, 2021
MONDAY, APRIL 5, 2021 | AGENDA
-- all times Eastern Standard –
7:30 – 8:00 | LONGWOOD FUND INTRODUCTION
8:00 – 8:20 | MANAGING HEALTH SYSTEMS IN A NEW ERA
Tom Sequist, Chief Patient Experience & Equity Officer, Mass General Brigham; Kevin Tabb, CEO, Beth Israel Lahey
Moderator: David Steinberg, General Partner, Longwood Fund
8:20 – 8:50 | STRATEGY IMPLEMENTATION: FROM NEWCO TO ESTABLISHED
Jeff Goldberg, CEO, Immunitas; David Southwell, CEO, TScan Therapeutics; Lara Sullivan, CEO, Pyxis Oncology; K. Dane Wittrup, Professor, Chemical & Biological Engineering, Koch Institute
8:50 – 9:20 | A NEW ERA OF COLLABORATION AND ENHANCED TRANSPARENCY
Percival Barretto-Ko, CBO, Astellas Pharma; Julie Gerberding, Chief Patient Officer, Merck & Co., former Director, CDC; Joanne Waldstreicher, CMO, Johnson & Johnson
9:20 – 9:50 | INNOVATION IN THE ROLE OF MANUFACTURING
Jason Kelly, CEO, Ginkgo Bioworks; Rahul Singhvi, CEO, Resilience; Mark Stevenson, COO, Thermo Fisher Scientific
Moderator: JC Gutierrez-Ramos, SVP & CSO, Danaher Corporation
9:50 – 10:20 | EXPEDITING RESEARCH FOR TREATMENTS AND CURES
Charles Albright, CSO, Affinia Therapeutics; Jessica Grossman, CEO, IgGenix; Brad Margus, CEO, Cerevance; Rich Moscicki, EVP, Science & Regulatory Advocacy, CMO, PhRMA; Rogerio Vivaldi, CEO, Sigilon
Moderator: George Daley, Dean, Harvard Medical School
10:20 – 10:50 | FIRESIDE CHAT
Alexander Hardy, CEO, Genentech; Emmanuel Ligner, CEO, Cytiva
Moderator: David Steinberg, General Partner, Longwood Fund
10:40 – 11:10 | IDENTIFYING NOVEL TECHNOLOGY
Rafael Amado, EVP, Head of R&D & CMO, Allogene; Maria Fardis, CEO, Iovance; Brett Monia, CEO, Ionis Pharmaceuticals; Alan Sachs, CSO, Thermo Fisher Scientific; Tarek Samad, CSO, Immunitas
Moderator: Michal Preminger, Head, E. North America, Johnson & Johnson Innovation
11:10 – 11:30 | FIRESIDE CHAT
Mathai Mammen, Global Head, R&D, Janssen; George Yancopoulos, President & CSO, Regeneron, Tal Zaks, CMO, Moderna
Moderator: Christoph Westphal, General Partner, Longwood Fund
11:30 – 12:00 | THE EVOLVING NEEDS OF R&D
Hal Barron, Head, R&D, GlaxoSmithKline; Jay Bradner, President, Novartis Institutes for BioMedical Research; Aakanksha Khandelwal, Head, Global Portfolio Strategy & Innovation, EMD Serono; Frank Nestle, Global Head, Research, CSO, Sanofi
Moderator: Ray Deshaies, Head, Global Research, Amgen
12:00 – 12:20 | FIRESIDE CHAT
Levi Garraway, CMO, Roche; John Maraganore, CEO, Alnylam; Janet Woodcock, Commissioner, FDA
Moderator: Christoph Westphal, General Partner, Longwood Fund
12:20 – 12:50 | ALTERNATIVE SOURCES OF FUNDING
Mike Boyle, CEO, Cystic Fibrosis Foundation; Sophie Kornowski, Senior Partner, Gurnet Point Capital; Paul Lammers, CEO, Triumvira; Stephen Lesser, Vice President, NovaQuest
12:50 – 1:20 | GOING GLOBAL: WORKING ACROSS INTERNATIONAL MARKETS
Thierry Bernard, CEO, Qiagen; Aoife Brennan, CEO, Synlogic; Ivan Cheung, Chair & CEO, Eisai US; Björn Frendéus, CSO, BioInvent
Moderator: Stephen Uden, Co-Founder, RallyBio
1:20 – 1:50 | TAPPING INTO INNOVATION: BIOPHARMA HUBS
John Flavin, CEO, Portal Innovations; Joel Marcus, Chair, Alexandria Real Estate; Lloyd Minor, Dean, Stanford School of Medicine; Iskra Reic, EVP, Europe & Canada, AstraZeneca
Moderator: Chandra Ramanathan, Global Head, Pharma R&D, Open Innovation, Bayer
1:50 – 2:20 | DIVERSITY, INCLUSION, AND EQUITY IN BIOPHARMA
Alisha Alaimo, President, US, Biogen; Charlotte Jones-Burton, VP, Global Clinical Development, Otsuka Pharmaceuticals; Rob Perez, Founder & Chair, Life Science Cares
Moderator: Ron Cooper, CEO, Albireo Pharma
2:20 – 2:50 | DESIGNING THE DEAL
Phil McGurk, Head, East Coast BD & Acquisitions, AbbVie; Lonnie Moulder, Founding General Partner, Tellus BioVentures; Patrick Verheyen, Global Head, BD, Janssen; Jonathan York, VP, Global BD, Daiichi Sankyo
2:50 – 3:10 | FIRESIDE CHAT
Andy Plump, President, R&D, Takeda; John Reed, EVP, Global Head, RD, Sanofi
Moderator: Christoph Westphal, General Partner, Longwood Fund
3:10 – 3:40 | NAVIGATING REGULATORY CHALLENGES
Dietmar Berger, CMO, Global Head, Development, Sanofi; PJ Brooks, Program Director, NIH; Priti Hegde, CSO, Foundation Medicine; Lynn Kramer, Chief Clinical Officer, Eisai; John Orloff, EVP, Head, R&D, Alexion
Moderator: Art Krieg, CSO, Checkmate Pharmaceuticals
3:40 – 4:10 | THE UPS, DOWNS, AND UPS OF DRUG APPROVAL
JJ Bienaime, CEO, BioMarin; Barry Greene, CEO, Sage Therapeutics; Ted Love, CEO, Global Blood Therapeutics; Bill Mezzanotte, EVP, Head, R&D & CMO, CSL Behring; Raquel Mura, Head, R&D North America, Sanofi
Moderator: Gaurav Shah, CEO, Rocket Pharmaceuticals
4:10 – 4:30 | FIRESIDE CHAT
Ruxandra Draghia-Akli, Global Head, Global Public Health R&D, Johnson & Johnson; JC Gutierrez-Ramos, SVP & CSO, Danaher Corporation
Moderator: David Steinberg, General Partner, Longwood Fund
4:30 – 5:00 | AFTER IPO: MAINTAINING MOMENTUM
Al Beardsley, COO, Galera Therapeutics; Sarah Boyce, CEO, Avidity Biosciences; Pablo Cagnoni, CEO, Rubius Therapeutics; Dan Omstead, CEO, Tekla Capital Management
Moderator: Dan Paterson, COO & President, Verastem
5:00 – 5:10 | LONGWOOD FUND SUMMARY
TUESDAY, APRIL 6, 2021
7:00 – 7:30 | LONGWOOD FUND INTRODUCTION
7:30 – 8:00 | PROGRESS TOWARDS SUSTAINABLE VACCINES FOR COVID-19
Stan Erck, CEO, Novavax; Melissa Moore, Chief Strategy Officer, Moderna; Ryan Richardson, Chief Strategy Officer, BioNTech; Derrick Sim, Director, Vaccine Supply & Demand, Gavi, The Vaccine Alliance
Moderator: Michael Mina, Asst. Professor, Epidemiology, Harvard School of Public Health
8:00 – 8:30 | NOVEL THERAPEUTIC MODALITIES
Al Gianchetti, CEO, XyloCor; Bill Hinshaw, CEO, Axcella Health; Sekar Kathiresan, CEO, Verve; Laura Sepp-Lorenzino, CSO, Intellia; Angela Shen, CMO, Arcellx
Moderator: Roger Tung, CEO, Concert Pharmaceuticals
8:30 – 8:50 | FIRESIDE CHAT
Tyler Jacks, Director, MIT Koch Institute for Integrative Cancer Research; Bob Langer, Co-Founder, Moderna/Momenta, Nobelist, NAS; Phil Sharp, Co-Founder, Biogen/Alnylam, Nobelist, NAS; Jonathan Weissman, Whitehead Institute, MIT, NAS
Moderator: Christoph Westphal, General Partner, Longwood Fund
8:50 – 9:20 | BIG BIOPHARMA R&D
Teri Foy, SVP, IO & Cellular Therapy, Bristol Myers Squibb; Steve Hitchcock, Head, Research, Takeda; Philip Larsen, Global Head, Research, Bayer Pharmaceuticals
Moderator: Melinda Richter, Global Head, JLabs, Johnson & Johnson Innovation
9:20 – 9:50 | ENSURING DIAGNOSTIC ACCURACY AND EFFICIENCY
Joshua Ofman, CMO & External Affairs, Grail Bio; Mark Stevenson, COO, Thermo Fisher Scientific; David Walt, Professor, Biologically Inspired Engineering, Harvard Medical School
Moderator: Lea Hachigian, CEO, ImmuneID, Venture Partner, Longwood Fund
9:50 – 10:20 | DRIVING INNOVATION IN CELL THERAPY
Lea Hachigian, Venture Partner, Longwood Fund; Richard James, Associate Professor, University of Washington; Frances Eun-Hyung Lee, Associate Professor, Emory; David Rawlings, Director, Center for Immunity and Immunotherapies, Seattle Children's Research Institute; Jason Rhodes, Partner, Atlas Ventures
Moderator: Aleks Radovic-Moreno, Venture Partner, Longwood Fund
10:20 – 10:40 | FIRESIDE CHAT
Paul Anderson, Chief Academic Officer & SVP, Research, Brigham Health; Laurie Glimcher, CEO, Dana-Farber Cancer Institute
Moderator: David Steinberg, General Partner, Longwood Fund
10:40 – 11:10 | EXPEDITING THE PATH TO PATIENT CARE
Fiona Elwood, Head, Neuroscience, Novartis; Cedric Francois, CEO, Apellis; Eileen Maus, CEO, Renovia Inc; Maria Rivas, CMO, Merck KGaA; Clay Siegall, CEO, Seagen
Moderator: Jeremy Levin, CEO, Ovid Therapeutics
11:10 – 11:40 | LEVERAGING AI TO TRANSFORM DRUG DISCOVERY AND DEVELOPMENT
Jennifer Buell, President & CEO, Agenus; Annalisa D’Andrea, CSO, ImmuneID; Milind Kamkolkar, CDO, Cellarity
Moderator: Robert Gentleman, Founding Executive Director, Center for Computational Biomedicine, Harvard Medical School
11:40 – 12:00 | FIRESIDE CHAT
David Reese, EVP, R&D, Amgen; Rupert Vessey, President, Research & Early Development, Bristol Myers Squibb
Moderator: Christoph Westphal, General Partner, Longwood Fund
12:00 – 12:30 | EXTERNAL INNOVATION
Diana Gallagher, Head, External Innovation & New Indications, Biogen; Roger Palframan, Head, External Innovation, UCB; Priyanka Rohatgi, Managing Director, Ventures, Ipsen; Bob Silverman, CBO, Alloy Therapeutics; Joanne Smith-Farrell, CEO, Be Bio
Moderator: Uwe Schoenbeck, CSO, External R&D, Pfizer
12:30 – 1:00 | MAKING A BIG IMPACT WITH LIMITED RESOURCES
Jeb Keiper, CEO, Nimbus Therapeutics; Martin Mackay, CEO, RallyBio; Adelene Perkins, CEO, Infinity Pharmaceuticals; Neil Weir, CEO, Sitryx
Moderator: David Meek, CEO, FerGene
1:00 – 1:30 | SCIENTIFIC INNOVATION: LAUNCHING COMPANIES FROM ACADEMIA
Omar Abudayyeh, Fellow, McGovern Institute; George Church, Professor, Harvard Medical School; Bill Hait, Global Head, External Innovation, Johnson & Johnson; Rachel Haurwitz, CEO, Caribou Biosciences; Kai Wucherpfennig, Chair, Cancer Immunology and Virology, Dana-Farber Cancer institute
Moderator: Paul Schimmel, Professor, Cell & Molecular Biology, Scripps
1:30 – 1:50 | FIRESIDE CHAT
Francis deSouza, CEO, Illumina; Skip Virgin, CSO, Vir Biotechnology, NAS
Moderator: Christoph Westphal, General Partner, Longwood Fund
1:50 – 2:20 | ALIGNING PRIORITIES WITH THE BOARD
Anirvan Ghosh, CEO, Unity Biotechnology; Enoch Kariuki, BOD, Imago, Zentalis; Denitsa Milanova, CEO, Marble Therapeutics; Myrtle Potter, CEO, Sumitovant
Moderator: Ramani Varanasi, CEO, X-Biotix
2:20 – 2:50 | DIFFERENTIATION IN ONCOLOGY
Philip Astley-Sparke, CEO, Replimune; Axel Hoos, SVP, R&D Governance Chair & Head, Oncology, GlaxoSmithKline; Pearl Huang, CEO, Cygnal Therapeutics; Armon Sharei, CEO, SQZ Biotech; Zhen Su, SVP, Head, Global Oncology, Merck KGaA
Moderator: Teresa Bitteti, President, Oncology, Takeda
2:50 – 3:20 | INNOVATIVE PARTNERSHIPS
Henry Gosebruch, Chief Strategy Officer, AbbVie; Jennifer Giottonini Cayer, CBO, Pulmocide; Alban de La Sabliere, SVP, Global Head, Partnering, Sanofi; Doug Giordano, SVP, WWBD, Pfizer; Ioannis Sapountzis, Global Head, BD&L, Boehringer Ingelheim
Moderator: Kendra Rose, Head New BD, Bayer Pharmaceuticals
3:20 – 3:40 | PERSPECTIVES ON HEALTHCARE REFORM AND PRICING
Peter Kolchinsky, Managing Director, RA Capital; Peter Rubin, Executive Director, No Patient Left Behind
3:40 – 4:15 | DEALS WITHIN THE VENTURE NETWORK
Eugene Chiu, Senior Partner, Investments, In-Q-Tel; Ansbert Gadicke, Managing Director, MPM Capital; Kyle Lefkoff, General Partner, Boulder Ventures; Bob Nelsen, Managing Director, ARCH Venture Partners; Aleks Radovic-Moreno, Venture Partner, Longwood Fund; Jeff Stevens, Principal, Alexandria Venture Investments
4:15 – 4:30 | LONGWOOD FUND SUMMARY